Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Int Rev Psychiatry ; 36(1-2): 69-79, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38557343

RESUMEN

A common challenge people face in today's cross-cultural world is how to solve a series of adaptation problems caused by cultural conflict. Exploring Bruce Lee's successful cross-cultural experiences through psychobiography offers some inspiration and thoughts. How did Bruce Lee successfully integrate martial arts, symbolising the Eastern culture, with films representing the Western culture, finally propelling kung fu films onto the international stage? Numerous publicly available materials about Bruce Lee were collected for this study, and the research data were evaluated using thematic analysis. Bruce Lee's success benefitted from reconstructing cultural environment information and exercising his initiative to shape a new cultural environment. His life experiences reflect individual cognition behaviour and social and cultural environments as two aspects of a dynamic circulation system and show that the two have reached internal and spiralling harmony through mutual integration. In the context of the Oriental collectivism culture's family narrative, Chinese adults' personality development features the unique theme of 'inheritance and innovation'. Dealing with the relationship between self-actualisation and familism is another important and challenging task in developing the Chinese personality.


Asunto(s)
Comparación Transcultural , Personalidad , Adulto , Humanos , Pueblo Asiatico , Motivación , Desarrollo de la Personalidad
2.
Cancer Control ; 30: 10732748231170485, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37072373

RESUMEN

Objective: This study sought to determine the mean prognostic usefulness of seleniumphosphate synthase (SEPHS1) by investigating its expression in 33 human malignancies and its relationship to tumor immunity.Methods: The expression of selenophosphate synthase 1 (SEPHS1) in 33 human malignant tumors was examined using the Genotype-Tissue Expression (GTEx), Cancer Genome Atlas (TCGA), and TIMER databases. Furthermore, the TCGA cohort was used to investigate relationships between SEPHS1 and immunological checkpoint genes (ICGs), tumor mutation burden (TMB), microsatellite instability (MSI), and DNA mismatch repair genes (MMRs). To establish independent risk factors and calculate survival probabilities for liver hepatocellular carcinoma (LIHC) and brain lower-grade glioma (LGG), Cox regression models and Kaplan-Meier curves were utilized. Eventually, the Genomics of Cancer Drug Sensitivity (GDSC) database was used to evaluate the drug sensitivity in LGG and LIHC patients with high SEPHS1 expression.Results: Overall, in numerous tumor tissues, SEPHS1 was highly expressed, and it significantly linked with the prognosis of LGG, ACC, and LIHC (P < .05). Furthermore, in numerous cancers, SEPHS1 expression was linked to tumor-infiltrating immune cells (TIICs), TMB, MSI, and MMRs. According to univariate and multivariate Cox analyses, SEPHS1 expression was significant for patients with LGG and LIHC.Conclusion: High SEPHS1 expression has a better prognosis for LGG, while low SEPHS1 expression has a better prognosis for LIHC. Chemotherapy was advised for LGG patients, particularly for those with high SEPHS1 expression because it can predict how responsive patients will be to 5-Fluorouracil and Temozolomide. This interaction between SEPHS1 and chemoradiotherapy has a positive clinical impact and may be used as evidence for chemotherapy for LGG and LIHC patients.


Asunto(s)
Carcinoma Hepatocelular , Glioma , Neoplasias Hepáticas , Selenio , Humanos , Fosfatos
3.
Altern Ther Health Med ; 28(6): 36-41, 2022 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-35648695

RESUMEN

Context: Testing patients for estrogen-receptor (ER) expression has become an important factor in the prognosis and prediction of breast cancer. Many studies have shown that endocrine therapy has no benefit for breast-cancer patients with low ER (ER+) expression, in which the proportion of positively stained cells is 1% to 9%. Objective: The study intended to explore the response to endocrine therapy of ER+ breast-cancer patients and to evaluate the benefits of the clinical use of endocrine therapy for treatment. Design: The research team designed a retrospective analysis and reviewed the data and survival rates of patients with early breast cancer. Setting: The study took place at the Hebei Breast Disease Clinic at the Fourth Hospital of Hebei Medical University in Shijiazhuang, China. Participants: Eligible participants in the study were 862 patients were diagnosed at and admitted to the clinic with early, nonadvanced breast cancer between January and December 2012. Outcome Measures: Based on ER-expression levels, participants were divided into ER negative (ER-), which indicates no positive staining of cells; ER+; and ER positive (ER++)-high expression in which the proportion of positively stained cells is ≥10%. The clinicopathological characteristics and the survival rates of the three groups were compared. Results: The clinicopathological features were similar for the ER- and ER+ groups. Compared to participants in the ER++ group, participants in the ER+ group: (1) were in an earlier stage, (2) had larger tumors, (3) were more likely to be positive for human epidermal growth factor receptor-2 (HER-2), (4) had a higher expression rate of Ki-67, (5) had a lower progesterone-receptor (PR) expression rate, (6) were more likely to receive chemotherapy, and (7) were less likely to receive endocrine therapy. Regardless of whether a participant received endocrine therapy or not, the seven-year overall survival (OS) between the ER- group and the ER+ group showed no significant difference, but both were in a worse condition than the ER++ group (P = .026). Conclusions: The current study found that the clinicopathological features of ER+ breast cancers were different from those of ER++ breast cancers and similar to those of ER-negative breast cancers. The benefits of endocrine therapy for ER+ breast-cancer patients weren't obvious.


Asunto(s)
Neoplasias de la Mama , Receptores de Estrógenos , Neoplasias de la Mama/diagnóstico , Neoplasias de la Mama/tratamiento farmacológico , China , Femenino , Humanos , Pronóstico , Receptores de Estrógenos/metabolismo , Estudios Retrospectivos , Tasa de Supervivencia
4.
Eur J Pharmacol ; 862: 172626, 2019 Nov 05.
Artículo en Inglés | MEDLINE | ID: mdl-31445013

RESUMEN

Neferine has long been recognized as a medicinal herbal ingredient with various physiological and pharmacological activities. Although previous studies have reported its antithrombotic effect, the underlying mechanisms have not been thoroughly investigated. Since platelets play a key role in thrombosis, we investigated the effects of neferine on human platelet function and the potential mechanisms. Platelet aggregation, adhesion and spreading were performed to investigate the effect of neferine on inhibition of platelet function. Flow cytometry was used to determine platelet alpha granule secretion and integrin IIb/IIIa activation, as detected by CD62P (P-selectin) expression, PAC-1 and fibrinogen binding. Western blotting was utilized to investigate the effect of neferine on intracellular signaling of activated platelet. We found that neferine significantly suppressed platelet aggregation and remarkably promoted the dissociation of platelet aggregates induced by collagen, thrombin, U46619, ADP and adrenaline in a dose-dependent manner. Flow cytometry analysis showed that neferine inhibited thrombin-induced platelet P-selectin expression, PAC-1 and fibrinogen binding. In addition, neferine reduced the adhesion of human platelets on coated collagen under both static and shearing condition at an arterial shear rate of 40 dyne/cm2. Neferine also inhibited the spreading of human platelets on immobilized fibrinogen. Western blot analysis showed that neferine inhibited PI3K activation, and decreased the levels of phosphorylation of Akt, GSK3ß and p38 MAPK in platelets. In summary, neferine has the potential to be an antiplatelet and antithrombotic agent by inhibiting the PI3K-Akt-GSK3ß/p38 MAPK signaling pathway.


Asunto(s)
Bencilisoquinolinas/farmacología , Plaquetas/efectos de los fármacos , Medicamentos Herbarios Chinos/administración & dosificación , Inhibidores de Agregación Plaquetaria/farmacología , Agregación Plaquetaria/efectos de los fármacos , Adulto , Bencilisoquinolinas/uso terapéutico , Adhesión Celular/efectos de los fármacos , Evaluación Preclínica de Medicamentos , Femenino , Glucógeno Sintasa Quinasa 3 beta/metabolismo , Voluntarios Sanos , Humanos , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Masculino , Fosfatidilinositol 3-Quinasas/metabolismo , Fosforilación/efectos de los fármacos , Inhibidores de Agregación Plaquetaria/uso terapéutico , Proteínas Proto-Oncogénicas c-akt/metabolismo , Trombosis/tratamiento farmacológico , Adulto Joven , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
5.
Eur J Med Chem ; 136: 382-392, 2017 Aug 18.
Artículo en Inglés | MEDLINE | ID: mdl-28525839

RESUMEN

Reduction of hippocampal neurogenesis caused by aging and neurological disorders would impair neural circuits and result in memory loss. A new lead compound (N-trans-3',4'-methylenedioxystilben-4-yl acetamide 27) has been discovered to efficiently stimulate adult rats' neurogenesis. In-depth structure-activity relationship studies proved the necessity of a stilbene scaffold that is absent in highly cytotoxic analogs such as chalcones and heteroaryl rings and inactive analogs such as diphenyl acetylene and diphenyl ethane, and validated the importance of an NH in the carboxamide and a methylenedioxy substituent on the benzene ring. Immunohistochemical staining and biochemical analysis indicate, in contrast to previously reported neuroprotective chemicals, N-stilbenyl carboxamides have extra capacity for neuroproliferation-type neurogenesis, thereby providing a foundation for improving the plasticity of the adult mammalian brain.


Asunto(s)
Acetanilidas/farmacología , Descubrimiento de Drogas , Hipocampo/efectos de los fármacos , Neurogénesis/efectos de los fármacos , Extractos Vegetales/química , Estilbenos/farmacología , Acetanilidas/química , Acetanilidas/aislamiento & purificación , Animales , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Humanos , Masculino , Estructura Molecular , Ratas , Ratas Sprague-Dawley , Estilbenos/química , Estilbenos/aislamiento & purificación , Relación Estructura-Actividad
6.
Eur J Pharmacol ; 746: 63-9, 2015 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-25445049

RESUMEN

Loureirin A is a flavonoid extracted from Dragon׳s Blood that has been used to promote blood circulation and remove stasis in Chinese traditional medicine. However, the mechanisms of these effects are not fully understood. We explored the anti-platelet activity and underlying mechanism of loureirin A in vitro. Our results indicated that loureirin A negatively affected agonist-induced platelet aggregation such as collagen, collagen-related peptide (CRP), ADP and thrombin. Loureirin A inhibited collagen-induced platelet ATP secretion and thrombin-stimulated P-selectin expression in a dose-dependent manner. Platelet spreading on immobilized fibrinogen was significantly impaired in the presence of loureirin A. Immunoblotting analysis indicated that 100µM of loureirin A almost completely eliminated collagen-induced Akt phosphorylation at Ser473. Interestingly, a submaximal dose (50µM) of loureirin A had an additive inhibitory effect with the phosphoinositide 3-kinase (PI3K) inhibitor Ly294002 on collage-induced Akt phosphorylation in platelets. Taken together, loureirin A had an inhibitory effect on platelet activation, perhaps through an impairment of PI3K/Akt signaling.


Asunto(s)
Chalconas/farmacología , Inhibidores de Agregación Plaquetaria/farmacología , Proteínas Proto-Oncogénicas c-akt/metabolismo , Adenosina Trifosfato/metabolismo , Animales , Plaquetas/efectos de los fármacos , Plaquetas/fisiología , Fibrinógeno/química , Fibrinógeno/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Proteínas Inmovilizadas/química , Proteínas Inmovilizadas/metabolismo , Masculino , Ratones , Selectina-P/metabolismo , Fosforilación/efectos de los fármacos , Extractos Vegetales/química , Agregación Plaquetaria/efectos de los fármacos , Trombina/farmacología
7.
Zhongguo Zhong Yao Za Zhi ; 27(5): 357-60, 2002 May.
Artículo en Chino | MEDLINE | ID: mdl-12774326

RESUMEN

OBJECTIVE: To provide application basis of the Forsythia suspensa by studying the difference of HPLC-FP of F. suspensa fructification (medicinal materials). METHOD: Comparative work was done on F. suspensa produced in different areas, on different parts of Forsythia suspensa, and on the pseudo preducts with methods of HPLC-FP. RESULT: Different FP characteristics were shown respectively by different samples, which were from different producing areas, from different parts, and the pseudo products including the fructification of Syringa reticulata var. and F. viridissimac. CONCLUSION: The FP can be used to distinguish the F. suspensa coming from different producing areas and different sources.


Asunto(s)
Medicamentos Herbarios Chinos/química , Forsythia/química , Plantas Medicinales/química , Cromatografía Líquida de Alta Presión , Cromatografía en Papel/métodos , Contaminación de Medicamentos , Forsythia/clasificación , Frutas/química , Mapeo Peptídico , Especificidad de la Especie
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA